Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Novo Holdings A/S, a leading international life sciences investor, today announces that its portfolio company F2G Ltd. (F2G) has entered into a strategic collaboration with Shionogi & Co., Ltd. (Shionogi) to develop and commercialise its antifungal agent olorofim for invasive fungal infections, in Europe and Asia ...

Related Keywords

Boston ,Massachusetts ,United States ,Austria ,Denmark ,Copenhagen ,Køavn ,United Kingdom ,London ,City Of ,San Francisco ,California ,Naveed Siddiqi ,Eric Snyder ,Francesco Maria Lavino ,Validation Of Novo Holding ,Shionogi Co Ltd ,Partner At Novo Holdings ,Cg Ltd ,Us Food Drug Administration ,Senior Partner At Novo Holdings ,Novo Holdings ,Novo Holding ,Senior Partner ,Board Member ,Breakthrough Therapy Designation ,Drug Administration ,Board Director ,Inovo Venture ,Maria Lavino ,Chief Executive Officer ,Inovo Ventures ,